Abstract 14460: Mitochondrial Dysfunction is Involved in Diabetic Cardiomyopathy

Abstract

Introduction: Diabetes is a strong risk factor not only for cardiovascular disease (CVD) but also for the development of chronic kidney disease (CKD) and represents a large and threatening public health challenge. We previously reported the deficiency of heat shock proteins and translocase of inner mitochondrial membrane (TIM) proteins are involved in the pathogenesis of hypertensive and uremic cardiomyopathy. Hypothesis: In this study, we further study the mechanism of mitochondrial dysfunction in the development of CVD and diabetic cardiomyopathy in CKD. Methods: Commercially available primary human atrial and ventricular cardiac myofibroblast and primary human aortic endothelial cells from 3 different age-matched sources were used in our type 2 diabetic cell model, in vitro. Immunohistochemistry, western blotting, Next-Generation RNA Sequencing, and real-time polymerase chain reaction (qPCR) were used in our proposed study. Results: Our data show that ATP5F1E (ATP Synthase F1 Subunit Epsilon), and cAMP regulator, Phosphodiesterase 8B are significantly (P<0.01) preserved in the normal cardiac myofibroblast and aortic endothelial cell. In addition, gene expression of the key ATP synthesis: OPA1, MFN1, TIM, and inflammation marker: MSR1, WNT5 were also significantly (p<0.05) increased in the non-diabetic cardiac myofibroblast and aortic endothelial cell. We next showed that key PPAR pathway regulators, Perilipin 1 (PLIN1) and PPARγ were significantly (p<0.05) increased in our in vitro diabetic cell model. Furthermore, PPARγ inhibitor, FABP4 (fatty acid binding protein-4) which functions as an atherosclerosis promoter was significantly up-regulated in (p<0.05) the non-diabetic cardiac myofibroblast and aortic endothelial cell. Conclusions: Mitochondrial ATP production is the main energy source for intracellular metabolic pathways and our study shows that mitochondrial dysfunction and down-regulation of ATP production may inhibit the hydrolysis of the second messenger cAMP that promotes the development of CVD and diabetic cardiomyopathy in CKD.